Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
REDWOOD CITY, Calif., Feb. 07, 2017 -- Capnia, Inc. (NASDAQ:CAPN), a diversified healthcare company that develops and commercializes innovative diagnostics, devices and therapeutics addressing unmet medical needs, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present at the 19th Annual BIO CEO & Investor Conference on Tuesday, February 14, 2017 at 8:00 AM ET at the Waldorf Astoria Hotel in New York City.
The presentation will be webcast live and may be accessed by visiting the “Events & Presentations” section of the Company's website at www.capnia.com. The webcast will also be available on the Company’s website for a limited period of time following the conferences.
About Capnia
Capnia is a leading provider and developer of innovative healthcare products to be used for the screening, detection and treatment of medical conditions. Capnia’s flagship products are based on its proprietary technologies, which utilize precision metering of gas flow. Capnia currently markets Serenz® Allergy Relief in the UK. The CoSense® ETCO Monitor measures ETCO, which can be used to detect hemolysis and the Infant Solutions product line, including innovative pulmonary resuscitation devices for neonates and infants, are marketed globally. Capnia is also clinically evaluating its nasal, non-inhaled CO2 technology to treat trigeminally-mediated pain conditions such as cluster headache and trigeminal neuralgia. For more information, please visit www.capnia.com.
Investor Relations Contact: Michelle Carroll/Glenn Garmont Argot Partners (212) 600-1902 [email protected] [email protected]
